Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 9 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Prescribing Trends in Opioids - Introduction to Opioids | 11 | 6 |
| World Health Organization Pain Ladder | 11 | 2 |
| Opioids in Pain Management | 13 | 1 |
| Opioids Remain the Mainstay of Chronic Pain Treatment | 13 | 1 |
| Opioids Classification | 13 | 2 |
| Leading Opioids in the Market | 15 | 1 |
| Branded Generics Play a Major Role | 15 | 1 |
| Novel Drug Delivery Techniques Push Opioid Usage | 16 | 1 |
| Adverse Effects Associated with Opioids Restrain its Prescription | 16 | 1 |
| Prescribing Trends in Opioids - Overview | 17 | 25 |
| Factors in Opioid Prescription | 19 | 1 |
| Alternatives to Opioid Use | 20 | 1 |
| Advantages and Disadvantages of Opioids over the Alternatives | 20 | 1 |
| Opioid Analgesics | 20 | 3 |
| Non Opioid Analgesics | 23 | 1 |
| Formulations and Mode of Delivery for Opioids | 24 | 1 |
| Route of Administration | 24 | 1 |
| Oral Route | 24 | 1 |
| Sublingual and Buccal Route | 24 | 1 |
| Transdermal Route | 24 | 1 |
| Transmucosal | 24 | 1 |
| Aerosol | 24 | 1 |
| Intravenous Route | 25 | 1 |
| Intramuscular Route | 25 | 1 |
| Subcutaneous Route | 25 | 1 |
| Duration of Opioid Treatment | 25 | 1 |
| Drug Dosing | 25 | 1 |
| Patients Compliance | 26 | 1 |
| Trends in Opioids Prescription | 27 | 1 |
| Gold Standards for Opioid Prescription | 27 | 1 |
| Acute and Chronic Pain | 28 | 1 |
| Use of Opioid Medications for Acute Pain | 28 | 1 |
| Treatment of Acute Pain | 28 | 1 |
| Contraindications and Relative Contraindications | 29 | 1 |
| Use of Opioid Medications for Chronic Pain | 30 | 1 |
| Patient Assessment for Pain Management | 30 | 1 |
| Definition of Low, Moderate and Severe Pain | 31 | 1 |
| Regulations and Opioids Prescription | 31 | 1 |
| Impact of REMS on Opioids Prescription | 32 | 1 |
| What is REMS? | 32 | 2 |
| Implications of REMS | 34 | 1 |
| REMS for Opioids | 35 | 1 |
| Implications for Patients and Physicians | 36 | 1 |
| FDA Regulations Regarding Opioids | 37 | 1 |
| FDA Releases New REMS Proposal for Opioid Prescription Oversight | 37 | 1 |
| FDA Regulations on Opioid Combinations with Acetaminophen | 38 | 1 |
| Darvocet, Darvon (propoxyphene) Withdrawn from the Market | 38 | 1 |
| Risk Evaluation and Mitigation Strategy | 38 | 1 |
| Physicians Perspective of REMS | 38 | 1 |
| What is in REMS? | 39 | 1 |
| Differentiating physical dependence, tolerance and addiction | 40 | 1 |
| Future treatments and abuse deterrent formulations | 40 | 1 |
| FDA Rejects New Formulation | 41 | 1 |
| Prescribing Trends in Opioids - Post-operative Pain | 42 | 6 |
| Current Practice | 42 | 2 |
| Treatment Flow | 44 | 1 |
| Patients Indicated for Opioid Use | 44 | 1 |
| Prescription Share of Opioids in Moderate and Severe Post-operative Pain Patients | 45 | 1 |
| Prescription Trends | 46 | 1 |
| Post-operative Nausea and Vomiting | 46 | 1 |
| Drivers and Restraints for the Opioids Market for Post-operative Pain | 46 | 1 |
| Drivers for Prescribing Trends in Post-operative Pain | 47 | 1 |
| Substantial Unmet Need Increases Market Potential | 47 | 1 |
| Titration of Opioids is Convenient in a Surgical Facility | 47 | 1 |
| Restraints for Prescribing Trends in Post-operative Pain | 47 | 1 |
| Expansion of Minimally Invasive Surgical Procedures | 47 | 1 |
| Perioperative Side Effects | 47 | 1 |
| Prescribing Trends in Opioids - Osteoarthritis Pain | 48 | 5 |
| Current Practice | 48 | 1 |
| Treatment Flow | 49 | 1 |
| Patients Indicated for Opioid Use | 50 | 1 |
| Share of Opioids in Moderate and Severe Osteoarthritis Pain Patients | 50 | 1 |
| Drivers and Restraints for the Opioids Market for Osteoarthritis Pain | 51 | 1 |
| Drivers for Prescribing Trends in Osteoarthritis Pain | 52 | 1 |
| Aging Population | 52 | 1 |
| Rapid Increase of the Obesity Population | 52 | 1 |
| Lifestyle Changes Increase Incidence of Osteoarthritis | 52 | 1 |
| Restraints for Prescribing Trends in Osteoarthritis Pain | 52 | 1 |
| Opioids Associated with Several Side Effects | 52 | 1 |
| Prescribing Trends in Opioids - Cancer Pain | 53 | 5 |
| Current Practice | 53 | 1 |
| Treatment Flow | 54 | 1 |
| Patients Indicated for Opioid Use | 55 | 1 |
| Share of Opioids in Moderate and Severe Cancer Pain Patients | 55 | 1 |
| Drivers and Restraints for the Opioids Market for Cancer Pain | 56 | 1 |
| Drivers for Prescribing Trends in Cancer Pain | 56 | 1 |
| Rising Incidence of Cancer Drives the Market | 56 | 1 |
| New Modes of Delivery Improve Pain Management for a Longer Duration | 56 | 1 |
| Restraints for Prescribing Trends in Cancer Pain | 57 | 1 |
| Concerns over the Risks of Addiction Related to Drug Therapy Affect the Prescription Rate | 57 | 1 |
| Patient Fears that Pain Treatment will Interfere with Cancer Treatment | 57 | 1 |
| Prescribing Trends in Opioids - Neuropathic Pain | 58 | 5 |
| Current Practice | 58 | 1 |
| Treatment Flow | 59 | 1 |
| Patients Indicated for Opioid Use | 60 | 1 |
| Share of Opioids in Moderate and Severe Neuropathic Pain Patients | 60 | 1 |
| Drivers and Restraints for the Opioids Market for Neuropathic Pain | 61 | 1 |
| Drivers for Prescribing Trends in Neuropathic Pain | 61 | 1 |
| Aging Population and Increasing Prevalence of Diabetes and HIV | 61 | 1 |
| Increasing Treatment Seeking Behavior will Drive the Patient Volumes | 61 | 1 |
| Restraints for Prescribing Trends in Neuropathic Pain | 61 | 1 |
| Absence of Accurate Diagnostic Tools for Pain Detection Act as a Hindrance for Market Growth | 61 | 1 |
| Neuropathic Pain is Generally Common and does not Respond to Opioids | 62 | 1 |
| Prescribing Trends in Opioids - Low Back Pain | 63 | 4 |
| Current Practice | 63 | 1 |
| Treatment Flow | 63 | 1 |
| Patients Indicated for Opioid Use | 64 | 1 |
| Share of Opioids in Moderate and Severe Low Back Pain Patients | 64 | 1 |
| Drivers and Restraints for the Opioid Market for Low Back Pain | 65 | 1 |
| Drivers for Prescribing Trends in Low Back Pain | 65 | 1 |
| Rising Elderly Population will Drive the Market | 65 | 1 |
| Sedentary Lifestyle Increases Low Back Pain | 65 | 1 |
| Restraints for Prescribing Trends in Low Back Pain | 66 | 1 |
| Low Treatment Seeking Rate and Low Prescription Rate Restricts the Market | 66 | 1 |
| Prescribing Trends in Opioids - Opioid Abuse | 67 | 5 |
| Opioid Dependence | 67 | 1 |
| Opioid Abuse | 68 | 1 |
| Patient/Abuser | 68 | 1 |
| Diversion of Opioid Prescriptions | 68 | 1 |
| Regulations to Reduce the Abuse of Opioids | 69 | 1 |
| REMS strategies | 69 | 1 |
| Labeling | 69 | 1 |
| Urine Toxicological Screens for Opioids | 69 | 1 |
| Abuse Deterrent Formulations | 70 | 1 |
| Embeda | 70 | 1 |
| Remoxy | 70 | 1 |
| Oxecta | 71 | 1 |
| Prescribing Trends in Opioids - Major Drugs | 72 | 11 |
| Duragesic (fentanyl) | 72 | 1 |
| Mechanism of Action | 72 | 1 |
| Product Description: | 72 | 1 |
| Safety Issues | 72 | 1 |
| Ultram ER (tramadol hydrochloride) | 73 | 1 |
| Mechanism of Action | 73 | 1 |
| Product Description | 73 | 1 |
| Safety Issues | 73 | 1 |
| Efficacy Details | 73 | 1 |
| Pavinal-Atropine (oxycodone hydrochloride hydrate + hydrocotarnine hydrochloride + atropine sulfate) | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| Product Description: | 74 | 1 |
| Safety Issues | 74 | 1 |
| OxyContin (oxycodone hydrochloride) | 75 | 1 |
| Mechanism of Action | 75 | 1 |
| Product Description | 75 | 1 |
| Safety Issues | 75 | 1 |
| Efficacy Details | 75 | 1 |
| Vicodin (hydrocodone bitartrate + acetaminophen) | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| Product Description | 76 | 1 |
| Safety Issues | 76 | 1 |
| Buprelor (buprenorphine) | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| Product Description | 76 | 1 |
| Safety Issues | 77 | 1 |
| Dividol (viminolo parahydroxybenzoate) | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| Product Description: | 77 | 1 |
| Safety Issues | 77 | 1 |
| Filnarine SR (morphine sulfate pentahydrate) | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| Product Description | 78 | 1 |
| Safety Issues | 78 | 1 |
| Nalbuphine (nalbuphine hydrochloride) | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| Product Description | 78 | 1 |
| Safety Issues | 79 | 1 |
| Spasmoplus (propyphenazone) | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| Product Description | 79 | 1 |
| Safety Issues | 79 | 1 |
| Mypaid (dihydrocodeine) | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| Product Description | 79 | 1 |
| Safety Issues | 80 | 1 |
| Yantil (tapentadol hydrochloride) | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| Product Description | 80 | 1 |
| Safety Issues | 80 | 1 |
| Nucynta (tapentadol hydrochloride) | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| Product Description | 81 | 1 |
| Safety Issues | 81 | 1 |
| Efficacy Details | 82 | 1 |
| Prescribing Trends in Opioids - Pipeline Analysis | 83 | 5 |
| Introduction | 83 | 1 |
| Profiles of Key Late-Stage Drugs in the Opioids Market | 84 | 1 |
| Fentanyl Taifun - AKELA Pharma Inc. | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| Fentanyl Sublingual Spray - Insys Therapeutics, Inc. | 85 | 1 |
| Oxycodone Hydrochloride - Mundipharma International Limited | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| CEP-33237 Teva Pharmaceuticals (Cephalon, Inc.) | 85 | 1 |
| ELI-216 - Elite Pharmaceuticals, Inc. | 85 | 1 |
| Mechanism of Action | 86 | 1 |
| ALO-02 (Oxycodone-naltrexone) | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| Price Premium on New Dose Forms | 87 | 1 |
| Price Premium on Abuse Deterrent Formulations in the Pipeline | 87 | 1 |
| Prescribing Trends in Opioids - Appendix | 88 | 4 |
| Market Definitions | 88 | 1 |
| Abbreviations | 88 | 1 |
| Sources | 88 | 1 |
| Research Methodology | 89 | 2 |
| Coverage | 89 | 1 |
| Secondary Research | 90 | 1 |
| Primary Research | 90 | 1 |
| Pipeline Analysis | 90 | 2 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 91 | 1 |